
    
      Study is to evaluate the safety, reactogenicity, and immunogenicity fo the candidate
      Plasmodium falciparum malaria protein 10 (FMP010). Malaria-experienced adults will be
      enrolled and randomized into 2 groups. Subjects will receive full dose FMP010 antigen
      (approximately 50 Î¼g) in 0.5 mL AS01B adjuvant or licensed rabies vaccine Rabipur (by
      Novartis) supplied in single dose vials containing lyophilized antigen with 1.0 mL of diluent
      (sterile water) for injection.
    
  